by WolfsRoot | Dec 15, 2021 | Allgemein
Leading experts in bench-to-bedside research and clinical trials for autoimmune diseases will provide strategic input to advanceSciRhom’s drug candidates Munich, Germany, December 15, 2021 – SciRhom GmbH, an advanced startup dedicated to developing transformative...
by InfoScirhom | Nov 30, 2021 | Allgemein
The increased investment accelerates SciRhom’s roadmap towards IND approval for their first-in-class drug candidates, which promisesignificant improvement over current therapies for autoimmune diseases. Munich, Germany, November 30, 2021 – SciRhom GmbH, a developer of...
by InfoScirhom | Nov 18, 2021 | Allgemein
Launching the next phase of company growth, a new Chief Medical Officer will head up clinical development of proprietary anti-iRhom2 antibodies with the support of accomplished scientists, life science executives, and financial experts. Munich, Germany, November 18,...
by InfoScirhom | Nov 5, 2019 | Allgemein
Bench to bedside research provides a new business opportunity: Newly discovered antibodies against iRhom2 block several pro-inflammatory pathways simultaneously, promising significant improvement over current autoimmune therapies. Munich, Germany, November 5, 2019 –...
Recent Comments